|
Miromatrix Medical inc (NASDAQ: MIRO) |
|
Miromatrix Medical inc
MIRO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Miromatrix Medical Inc 's sales fell
by -9.83 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2874
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -8 %
Miromatrix Medical Inc net loss decreased from $-8 millions, to $-6 millions in III. Quarter 2023,
• More on MIRO's Growth
|
|
Miromatrix Medical Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 160.12 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 77.88.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.
• More on MIRO's Valuation
|
|
|
|
|
Miromatrix Medical Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 160.12 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 77.88.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.
Miromatrix Medical Inc Price to Book Ratio is at 5.96 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01
• More on MIRO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com